Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||28/09/2018|
|Rapid review completed||08/11/2018|
|Rapid Review outcome||A Full Pharmacoeconomic Assessment is recommended|
|Full pharmacoeconomic assessment commissioned by HSE||14/11/2018|
|Pre-submission consultation with Applicant||15/01/2019|
|Submission received from Applicant||31/05/2019|
|HTA assessment commenced||04/09/2019|
|Preliminary review sent to Applicant||02/10/2019|
|NCPE assessment re-commenced||06/11/2019|
|Factual accuracy sent to Applicant||28/02/2020|
|NCPE assessment re-commenced||09/03/2020|
|NCPE assessment completed||16/04/2020|
|NCPE assessment outcome||The NCPE recommends that Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.